HADHA and ovarian carcinoma: However, it is essential to acknowledge certain limitations in the study: it requires further clinical validation for HADHA’s prognostic marker potential, needs deeper exploration of molecular mechanisms and signaling pathways involved in HADHA-mediated effects on ovarian cancer progression.